UK Parliament / Open data

Mesothelioma Lump Sum Payments (Conditions and Amounts) (Amendment) Regulations 2021

My Lords, as usual, this annual debate on the uprating of mesothelioma and pneumoconiosis regs invokes passionate memories of our industrial heritage and a different time for health and safety. The long latency of these diseases, which others have referred to, means that it can be many years before an individual is aware that they have been infected and, given that the main cause of exposure to mesothelioma is asbestos, its continuing presence in so much of our built environment, such as schools in particular, makes it a risk to be managed not only now but well into the future.

The Control of Asbestos Regulations 2012 are the HSE’s latest offering to help with that, which is to be commended. It is clear that these regs before us today should be supported. It is of regret, however, that it has not been seen fit to narrow or eliminate the gap between compensation paid to sufferers and to dependants. It was originally the intention that this gap be eliminated once resources allowed. It is understood that the 2008 Act payments were to be funded from recoveries from civil compensation arrangements. Can the Minister therefore let us know what the current position is on this and how close we are to closing that gap?

The 2014 payment scheme grew out of concerns that it was proving difficult for individuals to access entitlement to compensation under employers’ liability insurance arrangements; the tracing of policies was difficult and may have been frustrated in part by the industry. Can the Minister tell us what headroom there is in these arrangements? The Minister will recall that the scheme was funded by a levy of 3% on the gross written premiums of the industry. What data does the DWP have on the aggregate amounts of claims for lump sum compensation for mesothelioma, which come under three headings: the 2014 Act, these regulations we are considering to date, and employers’ liability insurance payments?

We have acknowledged in the past the medical research going on with the support of the insurance industry in particular, encouraged by Members of your

Lordships’ House. If you look at the scientific and medical advances and endeavours in recent times, perhaps there is hope for sufferers of these diseases as well.

3.58 pm

About this proceeding contribution

Reference

810 cc78-9GC 

Session

2019-21

Chamber / Committee

House of Lords Grand Committee
Back to top